CEVEC Pharmaceuticals GmbH develops and exploits expression and production technologies for human proteins, vaccines, gene therapies and biological substances as well as related products (company purpose). The company is headquartered in Cologne and is registered in the Commercial Register B of the Local Court of Cologne under number HRB 34497; it is classified as a small corporation under § 267 (1) HGB. On average 59 employees were employed during the year (prior year: 62). The company's financial statements are included in the consolidated financial statements of Danaher Corp., Washington, USA.
die Entwicklung und Verwertung von Expressions- und Produktionstechnologien für humane Proteine, Vakzine, Gentherapeutika und biologische Stoffe sowie von entsprechenden Produkten sowie sämtliche damit zusammenhängenden und den Gesellschaftszweck fördernden Geschäfte.
Converted using the official Destatis and Eurostat correspondence tables; ISIC Rev. 4 is the United Nations' international industry classification.
This summary was generated with the help of AI. See our Data Quality Notice. Report error?
Source: German Commercial Register (Handelsregister) Köln Local Court, HRB 34497 (as of 3 November 2026)
| Name | Type | City |
|---|---|---|
| Benjamin Hessel | Geschäftsführer(in) | Hofheim am Taunus |
| Roman Necina | Geschäftsführer(in) | Wien |
| Jens Warnecke | Geschäftsführer(in) | Hainade |
Source: German Commercial Register (Handelsregister) Köln Local Court, HRB 34497 (as of 3 November 2026)
| Date | Event Type | Event |
|---|---|---|
| 06.08.2025 | Business Address Change | Edmund-Rumpler-Straße 5, 51149 Köln |
| 03.09.2024 | Gesellschaftsvertrag amended | Gesellschaftsvertrag |
| 30.04.2021 | Gesellschaftsvertrag amended | Gesellschaftsvertrag |
| Date | Type | Change | Total Capital |
|---|---|---|---|
| 30.04.2021 | Capital Increase | +129.791 € | 1.985.276 € |
| 20.03.2019 | Capital Increase | +439.748 € | 1.855.485 € |
| 30.06.2017 | Capital Increase | +109.641 € | 1.415.737 € |
Source: German Commercial Register (Handelsregister) Köln Local Court, HRB 34497 (as of 3 November 2026)
| Year | Revenue | Profit | Balance | Employees |
|---|---|---|---|---|
| 2025 | €1,447,939 | -€9,162,342 | €9,541,117 | — |
| 2024 | €2,754,646 | -€7,446,464 | €4,937,723 | — |
| 2023 | €10,681,042 | €1,890,637 | €6,588,069 | — |
| 2022 | small company1 | -€40,227,175 | €4,347,127 | — |
| 2021 | ≤ €12M1 | -€3,766,273 | €7,195,335 | — |
| 2020 | ≤ €12M1 | €1,390,170 | €7,213,671 | — |
| 2019 | small company1 | — | €5,479,279 | — |
| 2018 | small company1 | — | €3,091,994 | — |
| 2017 | small company1 | — | €2,754,122 | — |
| 2016 | small company1 | — | €2,029,676 | — |
1 Small companies are not required to publish a profit-and-loss statement (§ 326 (1) HGB). The figure shown is the statutory ceiling under § 267 HGB where the balance-sheet total makes it binding — a company may exceed at most one of the three size criteria.
Sign in to download data
Source: German Commercial Register (Handelsregister) Köln Local Court, HRB 34497 (as of 3 November 2026)
Charité Healthcare Services GmbH
Berlin · Sonstige Forschung und Entwicklung im Bereich Natur-, Ingenieur-, Agrarwissenschaften und Medizin
nova-Institut für politische und ökologische Innovation GmbH
Hürth · Forschung und Entwicklung im Bereich Biotechnologie
E-VITA GmbH
Dresden · Forschung und Entwicklung im Bereich Biotechnologie
| Cost type | Amount | Share |
|---|---|---|
| Personnel Costs | €5,595,234 | 64.1% |
| Material Costs | €2,485,368 | 28.5% |
| Depreciation | €582,241 | 6.7% |
| Interest & Similar | €72,827 | 0.8% |
